Under construction – not a live service
Sign in
Taking people in FranceNo phase

Studying Pyrophosphate and Blood Vessel Damage in Children With Kidney Disease

Studies pyrophosphate levels and blood vessel disease in children with chronic kidney disease.

Plain-language title generated from the registry record
Registry title: Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease

Key facts

Where
Nice, FranceSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 0 and 18 years old?

Source: NCT06300788, who can take part

Where in France

  • CHU Nice - Hopital de l Archet 2Nice, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Centre Hospitalier Universitaire de Nice
Trial code
NCT06300788
Record updated
27 July 2026
Original description
The investigator aim to identify the role of inorganic pyrophosphate and other anti-calcifying molecules in vascular disease in children with chronic kidney disease, with a view to developing therapeutic approaches aimed at limiting the onset of vasculopathy.Read full original descriptionShow less

Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease - PPi-DIA

The investigator aim to identify the role of inorganic pyrophosphate and other anti-calcifying molecules in vascular disease in children with chronic kidney disease, with a view to developing therapeutic approaches aimed at limiting the onset of vasculopathy.

Inclusion: All groups :; Minor patients (<18 years); Patients of both sexes; Informed patients and parents who have signed the informed consent form; Patients affiliated to social security; Control group :; Patients with no particular pathology undergoing surgery and receiving a preoperative check-up; CKD groups :; Patients on dialysis for more than 3 months, regardless of technique; Kidney transplant patients; Patients with CKD, whatever the cause.

Exclusion: Progressive cancer or kidney disease; Treatments that may modify PPi concentration (e.g. bisphosphonates).

ClinicalTrials.gov NCT06300788